(Q37725990)

22 August 2017

1 reference

title

Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins (English)

1 reference

22 August 2017

1 reference

1 reference

1 reference

1 reference

1 reference

Shiran Shapira

1

1 reference

22 August 2017

Victoria Lisiansky

series ordinal

2

1 reference

22 August 2017

Nadir Arber

series ordinal

3

1 reference

22 August 2017

Sarah Kraus

series ordinal

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

Expert Opinion on Investigational Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

19 Suppl 1

1 reference

22 August 2017

page(s)

S67-77

1 reference

22 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Immunotoxin treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Immunotoxins in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Recombinant immunotoxins in targeted cancer cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Immunotherapy and immunoescape in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Leukocyte-endothelial adhesion and angiogenesis in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

The protein tyrosine kinase family of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Panitumumab in colon cancer: a review and summary of ongoing trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

FDA drug approval summary: panitumumab (Vectibix).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Monoclonal antibodies in the treatment of advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Immunotoxins for targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

HER 2/neu protein expression in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

HER 2/neu expression and gene amplification in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Dual targeting of EGFR and HER-2 in colon cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Angiogenesis inhibitors in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Thermo-stability and antitumor activity on colon cancer cell lines of monoclonal anti-CEA antibody-saporin immunotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

CD24 plays an important role in the carcinogenesis process of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Antibody internalization studied using a novel IgG binding toxin fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Pegylation: engineering improved biopharmaceuticals for oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003737668

10.1517/13543781003737668

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference